EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pathophysiology in Systemic Sclerosis: Current Insights and Future Perspectives

Suzan Al-Gburi, Pia Moinzadeh, Thomas Krieg

Sclerosis · 27.05.2025 · 3 (2) · 17

DOI: 10.3390/sclerosis3020017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sclerosis, online erschienen am 27.05.2025. Verfasst von Suzan Al-Gburi und 2 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Köln Fortune, DFG, Deutsche Forschungsgemeinschaft.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Systemic sclerosis (SSc) is a rare connective tissue disease characterized by vasculopathy, autoimmunity, and fibrosis. Due to its low prevalence and heterogeneous clinical presentation, early diagnosis remains challenging, often delaying appropriate treatment. The disease progresses from microvascular dysfunction, manifesting as Raynaud’s phenomenon, to systemic fibrosis affecting multiple organs, including the lungs, gastrointestinal tract, heart, and kidneys. There have been considerable advancements in understanding the pathophysiology of the disease during the last few years and this has already resulted in the improvement of the therapeutic approaches used to control organ-specific manifestations. However, the underlying cause of the disease still remains incompletely elucidated.

Methods

Here, we summarize the current knowledge on the SSc pathogenesis.

Results

The pathophysiology involves an interplay of chronic inflammation, impaired vascular function, and excessive extracellular matrix deposition, leading to progressive organ damage. Endothelial dysfunction in SSc is driven by immune-mediated injury, oxidative stress, and the imbalance of vasoconstrictors and vasodilators, leading to capillary loss and chronic hypoxia. Autoantibodies against endothelial cells or other toxic factors induce apoptosis and impair angiogenesis, further exacerbating vascular damage. Despite increased angiogenic factor levels, capillary repair mechanisms are defective, resulting in progressive ischemic damage. Dysregulated immune responses involving Th2 cytokines, B cells, and macrophages contribute to fibroblast activation and excessive collagen deposition. Transforming growth factor-beta (TGF-β) plays a central role in fibrotic progression, while fibroblasts resist apoptosis, perpetuating tissue scarring. The extracellular matrix in SSc is abnormally stiff, reinforcing fibroblast activation and creating a self-perpetuating fibrotic cycle.

Conclusions

Advances in molecular and cellular understanding have facilitated targeted therapies, yet effective disease-modifying treatments remain limited. Future research should focus on precision medicine approaches, integrating biomarkers and novel therapeutics to improve patient outcomes.

Förderung

  • Köln Fortune
  • DFG
  • Deutsche Forschungsgemeinschaft
  • Edith Busch Foundation

Zitieren

APA

Al-Gburi, S., Moinzadeh, P., & Krieg, T. (2025). Pathophysiology in Systemic Sclerosis: Current Insights and Future Perspectives. Sclerosis, 3(2), 17. https://doi.org/10.3390/sclerosis3020017

Vancouver

Al-Gburi S, Moinzadeh P, Krieg T. Pathophysiology in Systemic Sclerosis: Current Insights and Future Perspectives. Sclerosis. 2025;3(2):17. doi:10.3390/sclerosis3020017

BibTeX
@article{AlGburi2025,
  author = {Al-Gburi, Suzan and Moinzadeh, Pia and Krieg, Thomas},
  title = {Pathophysiology in Systemic Sclerosis: Current Insights and Future Perspectives},
  journal = {Sclerosis},
  year = {2025},
  volume = {3},
  number = {2},
  pages = {17},
  doi = {10.3390/sclerosis3020017}
}
Kostenlos starten →